# Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT06790602** · PHASE2 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 43 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (mPDAC)

## Interventions

- **DRUG:** Cemiplimab Plus Gemcitabine

## Key facts

- **NCT ID:** NCT06790602
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-07
- **Final completion:** 2029-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06790602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06790602, "Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06790602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*